Alzamend Neuro, Inc. announced on September 16, 2026, that it regained compliance with Nasdaq Stock Market requirements. Nasdaq issued a formal notification letter on September 14, 2026, confirming the company satisfies Listing Rule 5550(b)(1).
The company reported $5,802,680 in stockholders’ equity in its latest quarterly filing. Alzamend submitted this report on September 10, 2026, for the period ended July 31, 2026. The company needed to demonstrate a minimum of $2.5 million in equity to maintain its listing.
This development removes the threat of delisting and closes the matter with the exchange. Alzamend had been in non-compliance since receiving its initial notification on March 20, 2026.